Department of General Surgery, Nanfang Hospital, Southern Medical University , Guangzhou, Guangdong, China.
Cancer Biol Ther. 2020 Aug 2;21(8):688-697. doi: 10.1080/15384047.2020.1762419. Epub 2020 May 26.
Despite recent progress in screening survival-related genes, there have been few attempts to apply methods based on cancer stem cells (CSCs) for prognosis. We aimed to identify a CSC-based model to predict survival in colorectal cancer (CRC) patients.
MATERIAL/METHODS: Differentially expressed genes between CRC and normal tissues and between CD133- and CD133+ cells were obtained from The Cancer Genome Atlas and Gene Expression Omnibus, and intersections were evaluated. Gene Ontology functional and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyzes were performed. STRING was used to investigate interactions between the encoded proteins and the Kaplan-Meier method to verify mRNAs associated with survival. A prognostic model based on CSCs was established via univariate and multivariate Cox regression. Receiver operating characteristic curve analysis was conducted to test the model's sensitivity and specificity. The KS test was applied to provide evidence for relationships between expression levels of nine mRNAs in our model and pathological stage.
In total, 155 common differentially expressed mRNAs were identified, and nine (AOC1, UCN, MTUS1, CDC20, SNCB, MAT1A, TUBB2B, GABRA4 and ALPP) were screened after regression analyses to establish a predictive model for classifying patients into high- and low-risk groups with significantly different overall survival times, especially for stage II and IV patients.
We developed a novel model that provides additional and powerful prognostic information beyond conventional clinicopathological factors for CRC survival prediction. It also provides new insight into the molecular mechanisms underlying the transition from normal tissues to CSCs and formation of tumor tissues.
尽管在筛选与生存相关的基因方面取得了一些进展,但很少有尝试应用基于癌症干细胞(CSC)的方法进行预后预测。我们旨在确定一种基于 CSC 的模型,以预测结直肠癌(CRC)患者的生存情况。
材料/方法:从癌症基因组图谱和基因表达综合数据库中获取 CRC 组织与正常组织之间以及 CD133-和 CD133+细胞之间差异表达的基因,并对其进行交集评估。进行基因本体论功能和京都基因与基因组百科全书通路富集分析。STRING 用于研究编码蛋白之间的相互作用,Kaplan-Meier 方法用于验证与生存相关的 mRNAs。通过单因素和多因素 Cox 回归建立基于 CSCs 的预后模型。接收者操作特征曲线分析用于测试模型的敏感性和特异性。KS 检验用于提供我们模型中九个 mRNAs 的表达水平与病理分期之间关系的证据。
总共鉴定出 155 个共同差异表达的 mRNAs,经过回归分析筛选出 9 个(AOC1、UCN、MTUS1、CDC20、SNCB、MAT1A、TUBB2B、GABRA4 和 ALPP),建立了一个预测模型,可将患者分为高风险和低风险组,两组患者的总生存时间存在显著差异,尤其是对于 II 期和 IV 期患者。
我们开发了一种新的模型,为 CRC 生存预测提供了除传统临床病理因素之外的额外且强大的预后信息。它还为从正常组织向 CSC 转化以及肿瘤组织形成的分子机制提供了新的见解。